Novartis’s $1.4 Billion Pacibekitug Bet Gets Positive Phase 2 Inflammation Readout

Novartis’s $1.4 billion acquisition of Tourmaline Bio has received an encouraging follow-up readout. Pacibekitug, the anti-IL-6 antibody that was the main strategic rationale for the purchase, maintained large reductions in high-sensitivity C-reactive protein through six months in a Phase 2 study of patients with chronic kidney disease and elevated inflammatory risk.

In TRANQUILITY, median time-averaged change from baseline in hs-CRP through day 180 was an increase of 7% with placebo, compared with reductions of 76% for pacibekitug 25 mg every 90 days, 85% for 50 mg every 90 days and 89% for 15 mg every 30 days. Each pacibekitug comparison with placebo had a p-value below 0.0001. The European Society of Cardiology listed the TRANQUILITY analysis in an Aug. 29 Hot Line session at ESC Congress 2026, where the six-month findings were presented by Deepak Bhatt of the Icahn School of Medicine at Mount Sinai.

The result matters to Novartis because it addresses the durability of inflammation suppression across both monthly and quarterly dosing. It does not yet establish that pacibekitug prevents heart attacks, strokes or cardiovascular death. TRANQUILITY was designed around biomarker effects and safety in a high-risk chronic kidney disease population, leaving the central clinical-outcomes question for a larger and longer Phase 3 study.

Six-month data extend the earlier 90-day signal

TRANQUILITY randomized 143 patients at 49 U.S. centers in a 1:1:1:1 ratio to placebo or one of three subcutaneous pacibekitug regimens: 25 mg every 90 days, 50 mg every 90 days or 15 mg every 30 days. Participants had stage 3 or 4 chronic kidney disease and elevated hs-CRP. Their mean age was 69, 64% were women, roughly 70% were taking statins and about 60% had diabetes, according to the congress reporting reviewed for this story.

The six-month analysis extends results that Tourmaline disclosed in May 2025. At 90 days, the study’s primary endpoint showed median time-averaged hs-CRP reductions of 75% with the 25 mg quarterly regimen, 86% with 50 mg quarterly and 85% with 15 mg monthly, compared with a 15% reduction on placebo. At day 90 itself, the corresponding reductions were 70%, 85% and 89% for the active-treatment groups. Those data were already available when Novartis agreed to buy Tourmaline, so the new readout is less about discovering an initial signal than about showing that the effect persisted over a longer treatment window.

Researchers also reported sustained reductions in additional inflammatory markers, as well as fibrinogen and lipoprotein(a), across the pacibekitug groups compared with placebo. No clear dose-related safety signal was identified through the six-month treatment period, and 2% of pacibekitug-treated participants discontinued the drug. The ClinicalTrials.gov record lists safety and tolerability follow-up through day 365, which means the Aug. 29 presentation should not be treated as the final word on longer-term safety.

The numerical hs-CRP reduction was largest in the monthly 15 mg group, but the study was structured to compare each regimen with placebo rather than to establish that one active schedule is clinically superior to another. That distinction is important for a drug whose commercial appeal partly rests on infrequent dosing. The quarterly regimens still produced large and statistically significant reductions through day 180, preserving the dosing argument that helped make pacibekitug attractive to Novartis.

Why the readout matters to Novartis’s $1.4 billion acquisition

Novartis agreed in September 2025 to acquire Tourmaline Bio for $48 per share in cash, valuing the company at approximately $1.4 billion on a fully diluted basis. The purchase was completed the following month, after about 92.94% of Tourmaline’s outstanding shares were tendered. Pacibekitug was the centerpiece of the rationale, giving Novartis a late-stage anti-IL-6 program aimed at residual inflammatory risk in atherosclerotic cardiovascular disease.

The acquisition did not buy an approved cardiovascular drug. It bought a clinical-stage company whose lead asset still needed to show that strong biomarker effects could be sustained and, eventually, converted into better patient outcomes. Novartis described pacibekitug as Phase 3-ready when the deal was announced, and its January 2026 investor materials said Phase 3 preparation was planned during 2026. The six-month TRANQUILITY data now answer one of the nearer-term development questions by showing that hs-CRP suppression did not fade after the original 90-day analysis.

That is useful evidence for a company that paid a substantial premium for a program centered on cardiovascular inflammation, but the financial significance should not be overstated. A durable biomarker response can support dose selection and trial planning, yet it does not establish the clinical benefit that would ultimately underpin regulatory approval, physician adoption and commercial value. The $1.4 billion figure also refers to the fully diluted value of Tourmaline as a company, not a stand-alone purchase price assigned solely to pacibekitug.

A Phase 3 outcomes trial remains the decisive test

Pacibekitug is a long-acting monoclonal antibody that binds interleukin-6, an upstream inflammatory cytokine. The development thesis is that reducing IL-6-driven inflammation may address cardiovascular risk that remains even when traditional risk factors such as cholesterol are treated. Hs-CRP is widely used as a marker of systemic inflammation, and patients with chronic kidney disease were a relevant population for TRANQUILITY because they face high cardiovascular risk and can have persistent inflammatory burden.

The new data strengthen the biological and dosing case without closing the efficacy question. A cardiovascular outcomes trial would need to test whether treatment actually reduces clinically meaningful events rather than merely lowering laboratory markers. Bhatt, the TRANQUILITY presenter, said the next focus is determining whether the biomarker effects translate into improved cardiovascular outcomes in a larger Phase 3 study.

Safety will also matter more as exposure expands from 143 Phase 2 participants to a much larger population followed for longer. The absence of a clear dose-related safety signal in TRANQUILITY is encouraging, but rare or delayed adverse effects are difficult to characterize in a study of this size. Likewise, changes in fibrinogen, lipoprotein(a) and other markers are supportive observations rather than substitutes for a trial designed around cardiovascular events.

For Novartis, the next concrete milestone is therefore the launch and eventual readout of a Phase 3 cardiovascular outcomes program. The company has signaled preparation for that step, but the sources inspected for this story do not give a definitive start date. After the Aug. 29 presentation, the Tourmaline acquisition has stronger evidence that pacibekitug can suppress inflammation for six months with infrequent dosing; proof that the $1.4 billion bet can change cardiovascular outcomes still lies ahead.